Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive Response to Registering Clinical Trials Seen (India)

This article was originally published in PharmAsia News

Executive Summary

India's medical research community has embraced the public registration of clinical trials, reports the latest issue of the British Medical Journal, and public registration today is the norm in India's clinical trial industry. Two years ago the International Committee of Medical Journal Editors (ICMJE) declared that only registered clinical trials would be considered as a reputable basis of published scientific articles. In response, registered worldwide clinical trials with the main U.S. database rose from 13,153 in 2005 to around 40,000 today. India-based researchers today have 467 clinical trials registered with the U.S. clinical trial registry. India's Council of Medical Research (ICMR) is working to create an India-specific national clinical trial registry. ICMR official Dr. Vasantha Muthuswamy says, "We are almost ready to launch the registry. It is undergoing a trial run." (Click here for more

You may also be interested in...

Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

EU MDR Panel Discussion: A Year Extra Is Not A Full Extra Year For The MDR - How To Survive Changing And Confusing Times

May 26 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts